GSK and CureVac in tie-up to address multiple emerging variants with one COVID-19 vaccine
UK based pharma group, GlaxoSmithKline, and German biotech, CureVac, have struck a €150m (US$180m) deal to jointly develop next generation mRNA vaccines for COVID-19; the goal is to address multi-variants with one vaccine.